is mounjaro a tirzepatide (tirzepatide) for the Treatment of Type 2 Diabetes, USA New Blockbuster Type 2 Medication

While preliminary evidence from case reports and small studies shows promise in reducing binge frequency, no GLP-1 agonist currently holds FDA approval for this indication

PMID: 38290907 17 Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management

(2) Increased Body Fat Reduced Strength Decreased Muscle Mass Poor Memory Declining Cognitive Function Less Quality Sleep Reduced Bone Density Younger adults usually dont see any major differences in GH production, except in cases of growth hormone deficiency

Altered neuroregulation of GH secretion in viscerally obese premenopausal women